Identifying de‐NEDDylation inhibitors: Virtual high‐throughput screens targeting SENP8

Protein modification can have far‐reaching effects. NEDDylation, a protein modification process with the protein NEDD8, stabilizes and modifies how the targeted protein interacts with other proteins. Its role in system regulation makes it a prime therapeutic target, and virtual high‐throughput screening has already identified new NEDD8 inhibitors. SENP8 matures the NEDD8 proenzyme into the active form and regulates NEDDylation by removing NEDD8 from over‐NEDDylated proteins. In this work, SENP8 inhibitor candidates were identified in two rounds of virtual high‐throughput screening. Of the ten candidates identified in the first round of screening, four were active in validation experiments to yield an experimental hit rate of 40%. Of the five candidates identified in the second round of screening, one was active in validation experiments to yield an experimental hit rate of 20%. Results indicate virtual high‐throughput screening improved hit rates over traditional high‐throughput screening. The SENP8 inhibitor candidates can be used to interrogate the NEDDylation regulation mechanism.

[1]  A. Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. , 2002, Physiological reviews.

[2]  Jean-Loup Faulon,et al.  The Signature Molecular Descriptor. 1. Using Extended Valence Sequences in QSAR and QSPR Studies , 2003, J. Chem. Inf. Comput. Sci..

[3]  Yi Sun,et al.  The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. , 2012, Cancer research.

[4]  Heng Tao Shen,et al.  Principal Component Analysis , 2009, Encyclopedia of Biometrics.

[5]  Shelly C. Lu,et al.  Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation , 2012, Hepatology.

[6]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[7]  Jean-Loup Faulon,et al.  Predicting protein-protein interactions using signature products , 2005, Bioinform..

[8]  Gang Fu,et al.  PubChem Substance and Compound databases , 2015, Nucleic Acids Res..

[9]  J Andrew McCammon,et al.  Protein flexibility and computer-aided drug design. , 2003, Annual review of pharmacology and toxicology.

[10]  B. Blagoev,et al.  Systematic in vivo RNAi analysis identifies IAPs as NEDD8-E3 ligases. , 2010, Molecular cell.

[11]  D. Lane,et al.  Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity , 2004, Cell.

[12]  F. Z. Watts,et al.  Nep1, a Schizosaccharomyces pombe deneddylating enzyme. , 2005, The Biochemical journal.

[13]  M. Hochstrasser,et al.  Evolution and function of ubiquitin-like protein-conjugation systems , 2000, Nature Cell Biology.

[14]  Jean-Loup Faulon,et al.  The signature molecular descriptor. 3. Inverse-quantitative structure-activity relationship of ICAM-1 inhibitory peptides. , 2003, Journal of molecular graphics & modelling.

[15]  V. D. da Silva,et al.  Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy. , 2010, Journal of molecular graphics & modelling.

[16]  Jonathan J. Chen,et al.  Developing an in silico pipeline for faster drug candidate discovery: Virtual high throughput screening with the Signature molecular descriptor using support vector machine models , 2017 .

[17]  E. Campbell,et al.  Central Role for Endothelial Human Deneddylase-1/SENP8 in Fine-Tuning the Vascular Inflammatory Response , 2013, The Journal of Immunology.

[18]  Jacob D. Durrant,et al.  Molecular dynamics simulations and drug discovery , 2011, BMC Biology.

[19]  Jacob D. Durrant,et al.  Computer-aided drug-discovery techniques that account for receptor flexibility. , 2010, Current opinion in pharmacology.

[20]  D. Pereira,et al.  Origin and evolution of high throughput screening , 2007, British journal of pharmacology.

[21]  Jean-Loup Faulon,et al.  Stochastic Generator of Chemical Structure. 1. Application to the Structure Elucidation of Large Molecules , 1994, Journal of chemical information and computer sciences.

[22]  Jean-Loup Faulon,et al.  Data mining PubChem using a support vector machine with the Signature molecular descriptor: classification of factor XIa inhibitors. , 2008, Journal of molecular graphics & modelling.

[23]  Anindya Dutta,et al.  NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. , 2010, Cancer research.

[24]  R. Hay,et al.  NEDP1, a Highly Conserved Cysteine Protease That deNEDDylates Cullins* , 2003, Journal of Biological Chemistry.

[25]  E. Yeh,et al.  Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFκB-dependent transcription , 2006, Nature Cell Biology.

[26]  Jinfang Zhang,et al.  hCINAP is a novel regulator of ribosomal protein-HDM2-p53 pathway by controlling NEDDylation of ribosomal protein S14 , 2014, Oncogene.

[27]  Jean-Loup Faulon,et al.  Developing a methodology for an inverse quantitative structure-activity relationship using the signature molecular descriptor. , 2002, Journal of molecular graphics & modelling.

[28]  Mario R. Eden,et al.  Reverse problem formulation approach to molecular design using property operators based on signature descriptors , 2010, Comput. Chem. Eng..

[29]  Shi-Chung Chang,et al.  The Molecular Determinants of NEDD8 Specific Recognition by Human SENP8 , 2011, PloS one.

[30]  Ruben Abagyan,et al.  A natural product-like inhibitor of NEDD8-activating enzyme. , 2011, Chemical communications.

[31]  Corinna Cortes,et al.  Support-Vector Networks , 1995, Machine Learning.

[32]  Luming Yin,et al.  Identification and Characterization of DEN1, a Deneddylase of the ULP Family* , 2003, Journal of Biological Chemistry.

[33]  W. Guida,et al.  The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.

[34]  Vikrant A. Dev,et al.  Structure Generation of Candidate Reactants Using Signature Descriptors , 2014 .

[35]  Yanli Wang,et al.  PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..

[36]  Kurt Hornik,et al.  kernlab - An S4 Package for Kernel Methods in R , 2004 .

[37]  Keiji Tanaka,et al.  The NEDD8 system is essential for cell cycle progression and morphogenetic pathway in mice , 2001, The Journal of cell biology.

[38]  Bhuvanesh Singh,et al.  SCCRO (DCUN1D1) Promotes Nuclear Translocation and Assembly of the Neddylation E3 Complex* , 2011, The Journal of Biological Chemistry.

[39]  N. Chemmangattuvalappil,et al.  A Novel Methodology for Property-Based Molecular Design Using Multiple Topological Indices , 2013 .

[40]  Matthew L. Danielson,et al.  Computer-aided drug design platform using PyMOL , 2011, J. Comput. Aided Mol. Des..

[41]  Zongwei Li,et al.  The multifaceted regulation and functions of PKM2 in tumor progression. , 2014, Biochimica et biophysica acta.

[42]  B. Delaval,et al.  The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity , 2016, Scientific Reports.

[43]  Darrell Whitley,et al.  A genetic algorithm tutorial , 1994, Statistics and Computing.

[44]  Yun He,et al.  Learning from the Data: Mining of Large High-Throughput Screening Databases , 2006, J. Chem. Inf. Model..

[45]  Jonathan J. Chen,et al.  Pharmaceutical Machine Learning: Virtual High-Throughput Screens Identifying Promising and Economical Small Molecule Inhibitors of Complement Factor C1s , 2018, Biomolecules.

[46]  M. Roussel,et al.  E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification. , 2009, Molecular cell.

[47]  G. Morgan,et al.  Bortezomib (Velcade™) in the Treatment of Multiple Myeloma , 2006, Therapeutics and clinical risk management.

[48]  M. Dasso,et al.  Modification in reverse: the SUMO proteases. , 2007, Trends in biochemical sciences.

[49]  Ola Spjuth,et al.  Ligand-Based Target Prediction with Signature Fingerprints , 2014, J. Chem. Inf. Model..

[50]  W. Gu,et al.  FBXO11 Promotes the Neddylation of p53 and Inhibits Its Transcriptional Activity* , 2007, Journal of Biological Chemistry.

[51]  Dik-Lung Ma,et al.  Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening. , 2012, Biochimie.

[52]  G. Labesse,et al.  LEA3D: a computer-aided ligand design for structure-based drug design. , 2005, Journal of medicinal chemistry.

[53]  C. Chien,et al.  DEN1 deneddylates non-cullin proteins in vivo , 2008, Journal of Cell Science.

[54]  L. Jeong,et al.  Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells , 2015, Cancer biology & therapy.

[55]  I. Sumara,et al.  The human Dcn1-like protein DCNL3 promotes Cul3 neddylation at membranes , 2009, Proceedings of the National Academy of Sciences.

[56]  John J. Irwin,et al.  ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..

[57]  N. Wei,et al.  DEN1 Is a Dual Function Protease Capable of Processing the C Terminus of Nedd8 and Deconjugating Hyper-neddylated CUL1* , 2003, Journal of Biological Chemistry.

[58]  Y. Gotoh,et al.  NEDDylation controls the target specificity of E2F1 and apoptosis induction , 2013, Oncogene.

[59]  M. Ohh,et al.  Mdm2-mediated NEDD8 Modification of TAp73 Regulates Its Transactivation Function* , 2006, Journal of Biological Chemistry.

[60]  T. Toda,et al.  Covalent modifier NEDD8 is essential for SCF ubiquitin‐ligase in fission yeast , 2000, The EMBO journal.

[61]  Luca Scrucca,et al.  GA: A Package for Genetic Algorithms in R , 2013 .

[62]  B. Mahata,et al.  Recruitment of RPL11 at promoter sites of p53-regulated genes upon nucleolar stress through NEDD8 and in an Mdm2-dependent manner , 2012, Oncogene.

[63]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[64]  Jean-Loup Faulon,et al.  The Signature Molecular Descriptor. 2. Enumerating Molecules from Their Extended Valence Sequences , 2003, J. Chem. Inf. Comput. Sci..

[65]  S. Jentsch,et al.  A novel protein modification pathway related to the ubiquitin system , 1998, The EMBO journal.

[66]  Andreas Bender,et al.  Similarity Searching of Chemical Databases Using Atom Environment Descriptors (MOLPRINT 2D): Evaluation of Performance , 2004, J. Chem. Inf. Model..

[67]  H. Kawasaki,et al.  A new NEDD8-ligating system for cullin-4A. , 1998, Genes & development.

[68]  Ola Spjuth,et al.  Benchmarking Study of Parameter Variation When Using Signature Fingerprints Together with Support Vector Machines , 2014, J. Chem. Inf. Model..

[69]  A. Nakashima,et al.  X‐linked inhibitor of apoptosis protein mediates neddylation by itself but does not function as a NEDD8–E3 ligase for caspase‐7 , 2012, FEBS letters.

[70]  Yi Sun,et al.  Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells , 2016, Scientific Reports.

[71]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[72]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[73]  M. Goebl,et al.  Modification of yeast Cdc53p by the ubiquitin-related protein rub1p affects function of the SCFCdc4 complex. , 1998, Genes & development.

[74]  J. Mccammon,et al.  Accounting for Receptor Flexibility and Enhanced Sampling Methods in Computer‐Aided Drug Design , 2013, Chemical biology & drug design.

[75]  Jun Du,et al.  c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-β type II receptor. , 2013, Molecular cell.

[76]  C. Dobson Chemical space and biology , 2004, Nature.

[77]  J. Drews Drug discovery: a historical perspective. , 2000, Science.

[78]  Chao Ning,et al.  Performance Gains in Genome-Wide Association Studies for Longitudinal Traits via Modeling Time-varied effects , 2017, Scientific Reports.

[79]  D. Triggle Drug Discovery and Delivery in the 21st Century , 2006, Medical Principles and Practice.

[80]  Richard Pazdur,et al.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. , 2003, The oncologist.

[81]  Geng-Hung Liu,et al.  NEDDylation regulates E2F‐1‐dependent transcription , 2012, EMBO reports.

[82]  Yanli Wang,et al.  Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review , 2012, The AAPS Journal.

[83]  Qiang Hu,et al.  Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. , 2016, Blood.

[84]  Huahui Zeng,et al.  Alzheimer's disease drug development based on Computer-Aided Drug Design. , 2016, European journal of medicinal chemistry.

[85]  M. Estelle,et al.  The ubiquitin-related protein RUB1 and auxin response in Arabidopsis. , 1998, Science.

[86]  R. Barandelaa,et al.  Strategies for learning in class imbalance problems , 2003, Pattern Recognit..

[87]  Jonathan J. Chen,et al.  Identifying novel factor XIIa inhibitors with PCA-GA-SVM developed vHTS models. , 2017, European journal of medicinal chemistry.

[88]  John H. Van Drie,et al.  Computer-aided drug design: the next 20 years , 2007, J. Comput. Aided Mol. Des..

[89]  Hamed M. Kayello,et al.  An Application of Computer‐Aided Molecular Design (CAMD) Using the Signature Molecular Descriptor—Part 1. Identification of Surface Tension Reducing Agents and the Search for Shrinkage Reducing Admixtures , 2014 .

[90]  Donald P. Visco,et al.  Computer-aided molecular design using the Signature molecular descriptor: Application to solvent selection , 2010, Comput. Chem. Eng..

[91]  Yi-Ping Phoebe Chen,et al.  Structure-based drug design to augment hit discovery. , 2011, Drug discovery today.

[92]  Lingqiang Zhang,et al.  MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma , 2017, Scientific Reports.

[93]  Yi Pan,et al.  HybridDock: A Hybrid Protein-Ligand Docking Protocol Integrating Protein- and Ligand-Based Approaches , 2016, J. Chem. Inf. Model..

[94]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[95]  Derick C. Weis,et al.  The Signature Molecular Descriptor. 5. The Design of Hydrofluoroether Foam Blowing Agents Using Inverse-QSAR , 2005 .

[96]  Xin Chen,et al.  Performance of Similarity Measures in 2D Fragment-Based Similarity Searching: Comparison of Structural Descriptors and Similarity Coefficients , 2002, J. Chem. Inf. Comput. Sci..

[97]  T. Robak Bortezomib in the treatment of mantle cell lymphoma. , 2015, Future oncology.

[98]  M. Ohh,et al.  Chemotherapy induces NEDP1-mediated destabilization of MDM2 , 2010, Oncogene.